# First-in-Human Investigation of JMT108 Injection in Participants With Advanced Malignant Tumors

> **NCT06877650** · PHASE1,PHASE2 · RECRUITING · sponsor: **Shanghai JMT-Bio Inc.** · enrollment: 436 (estimated)

## Conditions studied

- Advanced Malignant Tumors

## Interventions

- **DRUG:** JMT108
- **DRUG:** Pembrolizumab
- **DRUG:** Ivonescimab

## Key facts

- **NCT ID:** NCT06877650
- **Lead sponsor:** Shanghai JMT-Bio Inc.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2025-04-11
- **Primary completion:** 2028-03-30
- **Final completion:** 2029-03-30
- **Target enrollment:** 436 (ESTIMATED)
- **Last updated:** 2026-01-29


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06877650

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06877650, "First-in-Human Investigation of JMT108 Injection in Participants With Advanced Malignant Tumors". Retrieved via AI Analytics 2026-07-20 from https://api.ai-analytics.org/clinical/NCT06877650. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*